Regenerative Medical Technology Group Inc. (RMTG)
OTCMKTS · Delayed Price · Currency is USD
0.0636
-0.0064 (-9.14%)
At close: Jul 29, 2026
RMTG Revenue
Regenerative Medical Technology Group had revenue of $2.64M in the quarter ending March 31, 2026, with 93.45% growth. This brings the company's revenue in the last twelve months to $6.38M, up 36.96% year-over-year. In the year 2025, Regenerative Medical Technology Group had annual revenue of $5.10M with 24.17% growth.
Revenue (ttm)
6.38M
Revenue Growth
+36.96%
P/S Ratio
0.13
Revenue / Employee
6.38M
Employees
1
Market Cap
835.64K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.10M | 992.82K | 24.17% |
| Dec 31, 2024 | 4.11M | 1.70M | 70.44% |
| Dec 31, 2023 | 2.41M | 879.73K | 57.49% |
| Dec 31, 2022 | 1.53M | 1.09M | 249.46% |
| Dec 31, 2021 | 437.89K | 382.81K | 694.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evofem Biosciences | 20.24M |
| SQZ Biotechnologies Company | 12.12M |
| Emmaus Life Sciences | 12.03M |
| Lyra Therapeutics | 398.00K |
| AXIM Biotechnologies | 92.90K |
| Halberd | 6.94K |
Regenerative Medical Technology Group News
- 6 days ago - RMTG Expands Cellgenic Operations Into Argentina, Establishing a Strategic Commercial Hub for Regenerative Medicine in Latin America - Accesswire
- 5 weeks ago - RMTG Launches ISSCA AI(TM) Clinical Intelligence Platform, Extending Its Global Regenerative Medicine Network Into AI-Driven Clinical Infrastructure - Accesswire
- 6 weeks ago - Global Stem Cells Group (OTC:RMTG) Launches ISSCA Mobile App, Advancing Its Buildout of a Global Digital Ecosystem for Regenerative Medicine - Accesswire
- 7 weeks ago - RMTG Surges 93% in Revenue, 87% in Gross Profit and 70% in Operating Income for Q1 2026 vs Q1 2025 - Accesswire
- 4 months ago - RMTG Subsidiary Cellgenic Commences Full-Scale Manufacturing at First-of-Its-Kind - Accesswire
- 9 months ago - RMTG Subsidiary CELLGENIC Introduces Peptide Pen Product Line at Cancún Global Summit - Accesswire
- 10 months ago - RMTG Subsidiary CELLGENIC Expands into Dominican Republic with New Distribution Partnership - Accesswire
- 10 months ago - RMTG Expands into Brazil with Strategic Representation Agreement - Accesswire